Holen Sie sich die Stockscreener-App
403.04
1.04%
-4.23
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Amgen Inc Stock (AMGN) Closed Down by 3.38% on Oct 1: What Investors Need To Know - TradingKey
More Than Skin Deep: Understanding Discoid Lupus Erythematosus - Amgen
Amgen (NASDAQ:AMGN) Scores Late-Stage Immunology Win - kalkinemedia.com
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Amgen reports Phase 3 results and Amgen stock trades at EUR 371.13 - AD HOC NEWS
Is Amgen (AMGN) Undervalued Following Its Phase 3 Sjögren's Disease Trial Update? - Simply Wall Street
Amgen Readies Daxdilimab For Phase III In Discoid Lupus After Mid-Stage Trial - insights.citeline.com
Homozygous Familial Hypercholesterolemia (HoFH)7MM Market, Epidemiology, and Forecast - GlobeNewswire Inc.
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody - Fierce Biotech
Amgen Inc (AMGN) Shares Surge 1.3% -- What GF Score of 87 Tells Investors - GuruFocus
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen (NASDAQ:AMGN) Stock: Dazodalibep's Phase 3 Win Targets a Disease With No Approved Medicines - kalkine.ca
Amgen Inc Agencies, 2017 - OpenSecrets
Amgen (NASDAQ:AMGN) Reports Positive Dazodalibep Data in Sjogren's - kalkinemedia.com
Amgen stock draws attention after a Phase 3 trial win - AD HOC NEWS
Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth? - Yahoo Finance
Amgen (AMGN), What Is Behind The Fresh Attention? - Yahoo Finance
Amgen Stock Forecast: Sjögren’s Trial Success Tests AMGN’s Pipeline Outlook - TradingKey
Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in Focus - Yahoo Finance
Amgen Inc Agencies, 2004 - OpenSecrets
Amgen (AMGN) Stock Forecast and Price Target 2026 - MarketBeat
Why Amgen’s Pipeline Just Got More Interesting - Yahoo Finance
Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back - Yahoo Finance
Amgen Inc Bills, 2008 - OpenSecrets
Amgen Inc. (AMGN) Stock forecasts - uk.finance.yahoo.com
Amgen Inc Agencies, 2011 - OpenSecrets
AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’ - stocktwits.com
How Phase 3 Sjögren’s Results At Amgen (AMGN) Has Changed Its Investment Story - Simply Wall Street
Amgen’s Deerfield office campus sold to Mesirow for $151M in sale-leaseback deal - Yahoo Finance
Yaron Werber: Celldex's Urticaria Drug Won't Carry a Black Box; Amgen Maps a $25 Billion Sjogren's Market - finance.biggo.com
Amgen (AMGN) Rises Higher Than Market: Key Facts - Yahoo Finance
Obesity Drug Sector Evolves as Amgen (AMGN) Advances Pipeline Am - GuruFocus
Mesirow buys Amgen’s Deerfield campus in $151 million sale-leaseback - Crain's Chicago Business
Amgen stock last at USD 410.86, up 1.19 percent in New York trading - AD HOC NEWS
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Yahoo Finance
Amgen stock trades at USD 406.04 after pipeline win - AD HOC NEWS
Amgen Inc. $AMGN Stock Purchased by Envestnet Portfolio Solutions Inc. - MarketBeat
Amgen stock heads into the open after a 0.01 percent loss - ad-hoc-news.de
Amgen Inc. (AMGN34.SA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Amgen Gains as Sjögren's Drug Clears Phase 3 - GuruFocus
Amgen (AMGN) Stock Could Be 40% Undervalued On Phase 3 Sjögren’s Data - simplywall.st
Amgen reports positive topline Phase 3 Sjögren’s results - European Pharmaceutical Review
Amgen stock heads into the open after a 4.34 percent gain - AD HOC NEWS
Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks - The Globe and Mail
Amgen (AMGN) Is Up 7.9% After Positive Phase 3 Dazodalibep Data in Systemic Sjögren’s Disease - Yahoo! Finance Canada
QRG Capital Management Inc. Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Envestnet Asset Management Inc. Acquires 326,260 Shares of Amgen Inc. $AMGN - MarketBeat
When Colorectal Cancer Strikes Early - Amgen
Amgen stock was last quoted after the close - AD HOC NEWS
Amgen price target raised by Jefferies to $410 after positive Sjögren's data - Yahoo Finance
Amgen says dazodalibep met Phase 3 Sjögren's endpoint - Mugglehead Investment Magazine
Amgen Stock Forecast: AMGN Reclaims $410 as Pipeline Catalysts Build - TradingKey
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study - Yahoo Finance
Jefferies Adjusts Amgen Price Target to $410 From $367, Maintains Hold Rating - marketscreener.com
Amgen Stock Gains After Announcing Positive Phase 3 Sjögren’s Disease Trial Results - TIKR.com
Canaccord reiterates Amgen stock Hold rating on pipeline win By Investing.com - Investing.com Canada
Amgen stock rises 4.34 percent as trial data lift pipeline hopes - AD HOC NEWS
Oppenheimer reiterates Amgen stock rating on positive trial data - Investing.com India
Jefferies raises Amgen stock price target on drug trial success - Investing.com India
Amgen (AMGN) Following Its Sjögren's Trial Win Through A Valuation Lens - simplywall.st
Amgen touts Phase III success in systemic Sjögren's disease - The Pharma Letter
What is changing in the investment case for Amgen (NASDAQ:AMGN)? - Kalkine Media
Ionis, Otsuka's Phase 3 win in ALS subtype; Boehringer's up to $1B cancer deal - Endpoints News
Amgen Inc. (NASDAQ:AMGN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Is Amgen Inc (AMGN) Overvalued After 4.3% Rally? GF Value Says O - GuruFocus
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):